It wasn't long agon when Elizabeth Holmes, the founder and CEO of Theranos, was regarded as one of the U.S.'s most successful female entrepreneurs with Forbes estimating her net work to be $4.5 billion. Thanks to all the evidence that Theranos' technology is largely a gimmick and false advertising, the publication has revised that figure to essentially zero, reports Quartz. From the report: Last year, Forbes pegged its value at $9 billion, based on the sale of stakes to investors. Since that lofty estimate, Theranos has been battered by bad news (paywalled; alternate source), starting with reports in the Wall Street Journal in October that its tests were inaccurate. That triggered an inquiry from the federal Centers for Medicare and Medicaid Services, which proposed banning Holmes from the industry. Forbes went back to its slide rule and, after talking to venture capitalists and industry experts, recalculated Theranos' value at $900 million, based on its intellectual property and money it has already raised. "At such a low valuation, Holmes' stake is essentially worth nothing," Matt Herper writes. That's because Theranos' other investors own preferred shares, and since Holmes owns common shares, they would get paid first if the company were forced to liquidate.